August 28, 2017 / 6:16 AM / a month ago

BRIEF-Poxel presents new preclinical Imeglimin data

Aug 28 (Reuters) - POXEL SA:

* PRESENTS NEW PRECLINICAL IMEGLIMIN DATA DEMONSTRATING IMPROVEMENT OF BOTH PERIPHERAL AND CORONARY VASCULAR FUNCTION AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS

* IMEGLIMIN HAS SUCCESSFULLY COMPLETED PHASE 1 AND PHASE 2 DEVELOPMENT IN OVER 1,200 SUBJECTS IN U.S., EU AND JAPAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below